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Patients (or Materials) and Methods: Three hundred twenty unre-
lated healthy individuals from Cuba and Nicaragua were included 
to analyze the CYP2D6 -1584C> G polymorphism using PCR-RFLP. 
These subjects were also previously genotyped for CYP2D6 and phe-
notyped for debrisoquine hydroxylation.1
Results: Individuals with -1584G allele had a lower metabolic ratio 
(log10 mean [SD]) than individuals with -1584C allele among carri-
ers of one (–0.13 [0.33] and 0.17 [0.52], respectively; P < 0.05) or 
2 (–0.32 [0.39] and –0.20 [0.44], respectively; P < 0.05) CYP2D6 
active genes. No differences were observed in individuals with > 2 
CYP2D6 active genes (–0.85 [0.69] and –0.59 [0.40], respectively).
Conclusion: CYP2D6 -1584C> G polymorphism was related with 
higher debrisoquine hydroxylation capacity in individuals with 1 or 
2 CYP2D6 active genes.
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Introduction: Epilepsy is treated with a variety of anticonvulsants 
including lamotrigine (LTG). Patients treated with antiepileptic drugs 
can exhibit large interindividual variability in clinical efficacy and 
adverse effects. LTG is widespread used for the treatment of partial 
and generalized epilepsy seizures. It is mainly metabolized by the 
phase II enzyme UGT1A4 (UDP-glucuronosyl transferase 1A4) to 
2-N-glucuronide. Functional studies of the 2 nonsynonymous genetic 
polymorphisms UGT1A4*2 (P24T) and UGT1A4*3b (L48V) have 
shown decreased enzyme activity on various substrates, including 
LTG.
Aims: To investigate the impact of UGT1A4*1b, UGT1A4*2 and 
UGT1A4*3b polymorphism on LTG plasma levels and clinical 
response in epileptic patients.
Patients (or Materials) and Methods: Forty-nine patients with epi-
lepsy (17–67 years old) treated with LTG gave informed consent 
to participate in the study. Nine patients were under monotherapy. 
Genomic DNA was extracted from peripheral blood samples by 
standard technique. Genotyping was performed by real-time PCR 
using allele-specific probes. LTG plasma levels were determined by 
HPLC analysis. Clinical response was evaluated by seizures control 
(responder, 0–1 seizure/month).
Results: The results of the present study showed a great interindi-
vidual variability in plasma levels between 1.1 and 22.3 µg/mL, even 
among patients under the same posology. The UGT1A4 genotype 
showed a tendency to modify the LTG plasma level, although no 
statistically difference was achieved (P = 0.1175). It was also found 
that .43% of the patients responded to treatment. Among mono-
therapy cases, the patient with the highest LTG plasma level (9.5 µg/
mL) exhibited UGT1A4 wt/*3b genotype.
Conclusion: Our results indicate that UGT1A4*1b, *2 y *3b poly-
morphism did not have an important impact in the clinical response 
to LTG in the 49 epileptic patients studied. Nevertheless, further 
investigations are needed with a larger sample.
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